神经母细胞瘤P-糖蛋白检测及其临床意义  

DETECTION OF P GLYCOPROTEIN IN NEUROBLASTOMA AND ITS CLINICAL SIGNIFICANCE

作　　者：郑修军[1] 江布先[1] 杨传民[1] 

机构地区：[1]青岛医学院附属医院儿外科

出　　处：《青岛医学院学报》1998年第1期10-12,共3页Acta Academiae Medicinae Qingdao Universitatis

基　　金：山东省教委基金

摘　　要：①目的检测神经母细胞瘤Ｐ－糖蛋白（Ｐ－ｇｐ）表达情况并探讨其临床意义。②方法用ＪＳＢ－１Ｐ－ｇｐ单克隆抗体ＳＬＡＢ法，测定１９例神经母细胞瘤石蜡切片的Ｐ－ｇｐ表达情况。③结果１９例神经母细胞瘤有１１例Ｐ－ｇｐ阳性（５７．９％）。术前化疗与术前无化疗的神经母细胞瘤Ｐ－ｇｐ阳性率间差别有显著性（χ２＝４．９２，Ｐ＜０．０５）。Ｐ－ｇｐ阳性组神经母细胞瘤病儿的平均生存时间为３２３ｄ，阴性组为７８９ｄ，二者具有明显差异（时序检验，Ｐ＜０．０５）。④结论Ｐ－ｇｐ表达是神经母细胞瘤产生耐药的原因之一。Objective To detect the expression of P glycoprotein in neuroblastoma by immunohistochemical method and to discuss its clinical significance. Methods 19 polyxine coated slides were stained with JSB 1 P glycoprotein monoclonal antibody by SLAB method. Results 11 out of 19 neuroblastomas (57.9%) were positive of P glycoprotein. The positive rate was significantly different between chemotherapeutic and chemotherpy free neuroblastomas preoperatively( χ 2=4.92, P< 0. 05). The average survive time was 323 days in P glycoprotein positive neuroblastoma group and 789 days in the P glycoprotein negative group. The difference between the two groups was significant(log rank test, P< 0.05). Conclusion Detectable P glycoprotein is the cause of drug resistance in neuroblastoma and the positivity of P glycoprotein appears to be an adverse prognostic factor.

关 键 词：神经母细胞瘤 P-糖蛋白 儿童 

分 类 号：R730.264[医药卫生—肿瘤] R73－361[医药卫生—临床医学]